All In Biotech

Drug Trial Radar · NCT06623136

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Apr 30, 2025

Primary completion

Feb 28, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • ES102Drug

    ES102 is administered via intravenous infusion, once every 21 days.

  • ToripalimabDrug

    Toripalimab is administered via intravenous infusion, once every 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) assessed by IRCTime frame: 1-2 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of He'nan University of Science and Technology

    Luoyang, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China

  • Taizhou Hospital

    Taizhou, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.